HIV and hepatitis C virus testing and treatment services in specialty treatment facilities that offer medication for opioid use disorder in the US

Eshan U. Patel; Becky L. Genberg; Xianming Zhu; Noa Krawczyk; Shruti H. Mehta; Aaron A.R. Tobian

doi:10.1001/jama.2022.0293

HIV and hepatitis C virus testing and treatment services in specialty treatment facilities that offer medication for opioid use disorder in the US

Eshan U. Patel, Becky L. Genberg, Xianming Zhu, Noa Krawczyk, Shruti H. Mehta, Aaron A.R. Tobian

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	776-778
Number of pages	3
Journal	JAMA
Volume	327
Issue number	8
DOIs	https://doi.org/10.1001/jama.2022.0293
State	Published - Feb 22 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2022.0293

Cite this

@article{0f19eb1928504b61ab9272707af9cc8d,

title = "HIV and hepatitis C virus testing and treatment services in specialty treatment facilities that offer medication for opioid use disorder in the US",

author = "Patel, {Eshan U.} and Genberg, {Becky L.} and Xianming Zhu and Noa Krawczyk and Mehta, {Shruti H.} and Tobian, {Aaron A.R.}",

note = "Funding Information: The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual census of federal, state, and local government facilities and private facilities that provide treatment services for alcohol and/or drug use in the United States, including the 50 states, the District of Columbia and other jurisdictions (e.g., the Commonwealth of Puerto Rico). N-SSATS is sponsored by the Substance Abuse and Mental Health Services Administration (SAMSHA) and is conducted by Mathematica Policy Research. N-SSATS survey design and procedures are publicly available.1-5 Funding Information: Funding/Support: This work was supported in part by the National Institute of Allergy and Infectious Diseases (grants R01AI120938, R01AI128779, and T32AI102623) and the National Institute on Drug Abuse (grant F31DA054849) of the National Institutes of Health. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. 1. Peters PJ, Pontones P, Hoover KW, et al; Indiana HIV Outbreak Investigation Team. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-239. doi:10.1056/NEJMoa1515195 2. Liang TJ, Ward JW. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169-1171. doi:10.1056/ NEJMp1716871 3. US Department of Health and Human Services. HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021-2025. Published January 15, 2021. Accessed January 11, 2022. https://hivgov-prod-v3.s3. amazonaws.com/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf 4. McNamara KF, Biondi BE, Hern{\'a}ndez-Ram{\'i}rez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8):ofab289. doi:10.1093/ofid/ofab289 5. Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA. 2013;310(24):2671-2672. doi:10.1001/jama. 2013.278456 6. Lerner AM, Fauci AS. Opioid injection in rural areas of the United States: a potential obstacle to ending the HIV epidemic. JAMA. 2019;322(11):1041-1042. doi:10.1001/jama.2019.10657",

year = "2022",

month = feb,

day = "22",

doi = "10.1001/jama.2022.0293",

language = "English (US)",

volume = "327",

pages = "776--778",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - HIV and hepatitis C virus testing and treatment services in specialty treatment facilities that offer medication for opioid use disorder in the US

AU - Patel, Eshan U.

AU - Genberg, Becky L.

AU - Zhu, Xianming

AU - Krawczyk, Noa

AU - Mehta, Shruti H.

AU - Tobian, Aaron A.R.

N1 - Funding Information: The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual census of federal, state, and local government facilities and private facilities that provide treatment services for alcohol and/or drug use in the United States, including the 50 states, the District of Columbia and other jurisdictions (e.g., the Commonwealth of Puerto Rico). N-SSATS is sponsored by the Substance Abuse and Mental Health Services Administration (SAMSHA) and is conducted by Mathematica Policy Research. N-SSATS survey design and procedures are publicly available.1-5 Funding Information: Funding/Support: This work was supported in part by the National Institute of Allergy and Infectious Diseases (grants R01AI120938, R01AI128779, and T32AI102623) and the National Institute on Drug Abuse (grant F31DA054849) of the National Institutes of Health. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. 1. Peters PJ, Pontones P, Hoover KW, et al; Indiana HIV Outbreak Investigation Team. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-239. doi:10.1056/NEJMoa1515195 2. Liang TJ, Ward JW. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169-1171. doi:10.1056/ NEJMp1716871 3. US Department of Health and Human Services. HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021-2025. Published January 15, 2021. Accessed January 11, 2022. https://hivgov-prod-v3.s3. amazonaws.com/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf 4. McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8):ofab289. doi:10.1093/ofid/ofab289 5. Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA. 2013;310(24):2671-2672. doi:10.1001/jama. 2013.278456 6. Lerner AM, Fauci AS. Opioid injection in rural areas of the United States: a potential obstacle to ending the HIV epidemic. JAMA. 2019;322(11):1041-1042. doi:10.1001/jama.2019.10657

PY - 2022/2/22

Y1 - 2022/2/22

UR - http://www.scopus.com/inward/record.url?scp=85125020351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125020351&partnerID=8YFLogxK

U2 - 10.1001/jama.2022.0293

DO - 10.1001/jama.2022.0293

M3 - Letter

C2 - 35191936

AN - SCOPUS:85125020351

SN - 0098-7484

VL - 327

SP - 776

EP - 778

JO - JAMA

JF - JAMA

IS - 8

ER -

HIV and hepatitis C virus testing and treatment services in specialty treatment facilities that offer medication for opioid use disorder in the US

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this